Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2023 > Vol 4, №8 (2023) > Personalized approach to the biologicals selection and therapy in patients with asthma and chronic rhinosinusitis with nasal polyps: clinical case analysis

Personalized approach to the biologicals selection and therapy in patients with asthma and chronic rhinosinusitis with nasal polyps: clinical case analysis

Ksenia S. Pavlova , Daria O. Timoshenko , Mariola A. Rodionova , Oksana M. Kurbacheva , Natalia I. Ilina

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are concomitant diseases that are based on common pathogenetic mechanisms and have negative impact on the each other severity. A modern strategy in the severe asthma and CRSwNP treatment is the use of biologicals – monoclonal antibodies that block various pathways of the T2-inflammation, which underlies the development of these diseases. Despite the fact that biologicals used in the asthma and CRSwNP treatment are highly effective and safe, they are not universal and have some limitations associated with their action mechanism. Hence, the biologicals selection should be personalized, taking into account all the patient’s phenotypic and endotypic characteristics. Moreover, an important condition for the effective and safe therapy with biologicals is dynamic observation with regular clinical and laboratory asessments. The importance of these aspects was shown by a clinical case.
Key words: asthma, chronic rhinosinusitis with nasal polyps, biologicals, biologics, monoclonal antibodies, dupilumab, mepolizumab, peripheral blood eosinophilia, hypereosiniphilia.

About the Author

Ksenia S. Pavlova 1 , Daria O. Timoshenko 1 , Mariola A. Rodionova 1 , Oksana M. Kurbacheva 2 , Natalia I. Ilina 3

1 National Research Center Institute of Immunology, Federal Medical and Biological Agency of Russia, Moscow, Russia

2 National Research Center Institute of Immunology, Federal Medical and Biological Agency of Russia, Moscow, Russia; Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

3 National Research Center Institute of Immunology, Federal Medical and Biological Agency of Russia, Moscow, Russia; Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow,

References

1. Fokkens W, Lund V, Bachert C et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019; 74: 2312–9. DOI: 10.1111/all.1387
2. Soler Z, Mace J, Litvack J et al. Chronic rhinosinusitis, race, and ethnicity. Am J Rhinol Allergy. 2012; 26 (2): 110–6. DOI: 10.2500/AJRA.2012.26.3741
3. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol. 2011; 128 (4): 693–707. DOI: 10.1016/J.JACI.2011.08.004
4. Khalmuratova R, Park JW, Shin HW. Immune Cell Responses and Mucosal Barrier Disruptions in Chronic Rhinosinusitis. Immune Netw. 2017; 17 (1): 60–7. DOI: 10.4110/IN.2017.17.1.60
5. Курбачева О.М., Дынева М.Е., Шиловский И.П. и др. Особенности молекулярных механизмов патогенеза бронхиальной астмы в сочетании с полипозным риносинуситом. Пульмонология. 2021; 31 (1): 7–19. DOI: 10.18093/0869-0189-2021-31-1-7-19
Kurbacheva OM, Dyneva ME, Shilovskiy IP et al. Pathogenetic molecular mechanisms of chronic rhinosinusitis with nasal polyps associated with asthma. Pulmonologiya. 2021; 31 (1): 7–19. DOI: 10.18093/0869-0189-2021-31-1-7-19 (in Russian).
6. Савлевич Е.Л., Курбачева О.М., Егоров В.И. и др. Уровень экспрессии генов цитокинов при разных фенотипах полипозного риносинусита. Вестник оториноларингологии. 2019; 84 (6): 42–7. DOI: 10.17116/otorino20198406142
Savlevich EL, Kurbacheva OM, Egorov VI et al. Gene expression levels of cytokines in different phenotypes of CRSwNP. Vestn Otorinolaringol. 2019; 84 (6): 42–7. DOI: 10.17116/otorino20198406142 (in Russian).
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023. Available at: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf [Accessed: November 17, 2023].
8. Шиловский И.П., Ерошкина Д.В., Бабахин А.А., Хаитов М.Р. Антицитокиновая терапия бронхиальной астмы. Молекулярная биология. 2017; 51 (1): 3–17. DOI: 10.7868/S0026898416060197
Shilovskiy IP, Eroshkina DV, Babakhin AA, Khaitov MR. Anticytokine therapy of allergic asthma. Mol Biol. 2017; 51 (1): 3–17. DOI: 10.7868/S0026898416060197 (in Russian).
9. Agache I, Song Y, Alonso-Coello P et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy. 2021; 76 (8): 2337–53. DOI: 10.1111/ALL.14809
10. Agache I, Beltran J, Akdis C et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75 (5): 1023–42. DOI: 10.1111/ALL.14221
11. Bachert C, Han J, Desrosiers M et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394 (10209): 1638–50. DOI: 10.1016/S0140-6736(19)31881-1
12. Дынева М.E., Аминова Г.Э., Курбачева О.М., Ильина Н.И. Дупилумаб: новые возможности в терапии бронхиальной астмы и полипозного риносинусита. Российский Аллергологический Журнал. 2021; 18 (1): 18–31. DOI: 10.36691/RJA1408
Dyneva ME, Aminova GE, Kurbacheva O, Il'ina NI. Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps. Russian Journal of Allergy. 2021; 18 (1): 18–31. DOI: 10.36691/RJA1408 (in Russian).
13. Курбачева О.М., Дынева М.Е., Ильина Н.И. Дупилумаб: основные аспекты применения при T2-опосредованных заболеваниях. Медицинский совет. 2021; (16): 186–96. DOI: 10.21518/2079-701X-2021-16-186-196
Kurbacheva OM, Dyneva ME, Ilina NI. Dupilumab: basic aspects and applications to T2-mediated diseases. Medical Council. 2021; (16): 186–96. DOI: 10.21518/2079-701X-2021-16-186-196 (in Russian).
14. Agache I, Akdis C, Akdis M et al. EAACI Biologicals Guidelines – Recommendations for severe asthma. Allergy. 2021; 76 (1): 14–44. DOI: 10.1111/ALL.14425
15. Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes. J Investig Allergol Clin Immunol. 2022; 32 (3): 165–80. DOI: 10.18176/jiaci.0823
16. Хаитов М.Р., Шиловский И.П. Антицитокиновая терапия аллергических заболеваний: молекулярно-иммунологические механизмы и клинические основы. М.: Медиа Сфера, 2021.
Khaitov MR, Shilovskiy IP. Anticitokinovaya terapiya allergicheskih zabolevanij: molekulyarno-immunologicheskie mekhanizmy i klinicheskie osnovy. Moscow: Media Sfera, 2021 (in Russian).
17. Han J, Bachert C, Fokkens W et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; 9 (10): 1141–53. DOI: 10.1016/S2213-2600(21)00097-7

For citation:Pavlova K.S., Timoshenko D.O., Rodionova M.A. et al. Personalized approach to the biologicals selection and therapy in patients with asthma and chronic rhinosinusitis with nasal polyps: clinical case analysis. Clinical review for general practice. 2023; 4 (8): 24–28 (In Russ.). DOI: 10.47407/kr2023.4.8.00327


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru